Novocure NVCR
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 61st percentile, 5-year average -52.2x
Near the bottom of its 5-year range · 14th percentile, 5-year average 9.4x
#4106 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 2nd percentile, 5-year average 6.9x
#2489 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.94 | – | 9.44 | 14% (cheaper than usual) | #4106 of 5330 (1 = cheapest) |
| PE | -11.16 | -14.34 | -52.21 | 61% (pricier than usual) | – |
| PS | 1.91 | 1.78 | 6.94 | 2% (cheaper than usual) | #2489 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NVCR.
Sign in to join the discussion.